DROGASIL
Transcrição
DROGASIL
Goiânia- Av. 85 São Paulo – Shopping Bourbon DROGASIL Ribeirão Preto- Bernardino de Campos Sorocaba BRAZIL DAY 2008- DROG3 – October 28, 2008 1 0 Presenters Paulo Sérgio Coutinho Galvão Filho Drogasil Member of the Board Brief Profile CEO of GL Holdings S/A. Shareholder and Member of the Board of Drogasil S/A since 1994. Partner of Klabin Irmãos & Cia. Member of the Board of Klabin Group. Board Member and Director of ABRASCA (Brazilian Association of PublicTraded Companies) and former Board member of BM&FBovespa S/A. Bachelor´s Degree from PUC-Pontifícia Universidade Católica São Paulo. Post Graduate Studies in Finance at University of California . Post Graduate Studies from Harvard Business School. Roberto Listik IR manager since 2007. Investor RelationsManager Thomson Financial representative for Brazil and Latin America Regions. Financial Career developed at Chase,Citibank , Banco Cidade and EDS in senior positions. Bachelor´s Degree and Post Graduated Studies from Fundação Getúlio Vargas- S.Paulo Brazil. 2 1 1935- Drogasil is founded on March 28, 1935, when owners of two small pharmacy chains, Drogaria Bráulio and Drogaria Brasil, combined their respective experience and financial resources to form a new company under the name Drogasil Ltda. 1972- Drogasil became a corporation (sociedade anônima) . 1977-, Drogasil became registered as a public company with the CVM(Brazilian SEC). 1979-, Drogasil is pioneer on developing self service concept on pharma retail sales. 2000- Drogasil speeds the information technology systems process to create a network linkage for all its stores with distribution center. In a turnaround process, implemented several other measures to increase the efficiency on inventory control, cash and sales activity reports. 2007- Drogasil register for the "Novo Mercado" listing segment, highest level of corporate governance at BM&FBovespa. 3 Drogasil HQ (1941) - Rua José Bonifácio, 166 - SP Drogasil: Snapshot Pharma Retail Leader in Brazil Overview Drogasil Stores in Brazill Drogasil has 73 years of presence in pharma cosmetics retail in Brazil.. Top 500 , ed 2008: ranked 365. Moved up 18 positions. D.F. Minas Gerais Second Largest drugstore chain in S.Paulo. # Stores: 27 4th Largest drugstore chain in Brazil. # Stores Logistics & Transport Goiás Goiá Goiás Geographic coverage on 1,000 km over 4 Brazilian States: 43 vehicles- own fleet. # Stores: 25 19 249 Stores. Minas Gerais DRUGS MARKET SHARE 9,93% 8,63% 7,53% São Paulo 5,98% 5,88% 3,87% 3,82% 3,49% São Paulo # Stores: - metropolitan area: Brasil S.Paulo Minas Gerais GOÍAS - Inner Cities 178 117 61 Legenda Distribution Center Stores Source: IMS Health- RD report Note: 1 June 2008, June 2007 June 2008 4 3 Drogasil :Shareholders SHAREHOLDERS PROFILE in the FREE FLOAT INTERNATIONAL 59,90% BRASIL 40,10% Carlos Pires Oliveira Dias 26,21% Free Float 41,36% Tantra Participações Ltda 10,34% Managers 6,78% Treasury 5,91% Regimar Comercial S.A 9,40% 1 2 Note: 1. 2. 3. 4. 5. Tantra - Lafer Galvão Family (100%) Oliveira Dias Familiy (100%) Stock Option Plan dilution up to 3,0% Stock Price: R$9,49 ( October 14, 2008) Buy Back Program Completed : total of 3,706,696 shares as of October 15, 2008. Outstanding Shares as of October 2008: 59.060 M shares Market Value: R$ 560,4 MM 4 5 4 KEY DRIVERS TOWARDS DROGASIL GROWTH Formal Economy: Tax Evasion Reduction 10,0% + GROWTH “Life Style ” Drugs patent expiration in 2008-2009. + Generic Drug market penetration growth. + + Brazilian population life expectancy growth. + Growing presence women in labour market. 6 5 VAT ADVANCE-ST Electronic Invoice The ICMS(VAT) Systematic- A Comparison - São Paulo VAT ADVANCE SALE PURCHASE BASE CAL Supplier Purchase Price ICMS Crédito( VAT Credit) ICMS Retido( VAT Advance) IVA (38,24% )=Base de Retenção ICMS Débito ( VAT Debit) CMV= COGS Rec. Vendas Brutas= Gross Sales Preço de Venda= Sales Price ICMS DEBITO= VAT DEBIT Venda Líquida= Net SALES GROSS MARGIN VALUE GROSS MARGIN ( Compared to Net Sales) GROSS MARGIN( Compared to Gross Sales) ICMS DEBITO= VAT DEBIT ICMS CREDITO=VAT CREDIT ICMS ANTECIPADO= VAT ADVANCED Total DEBIT CREDIT 18% 100.00 100.00 (18.00) 82.00 18% 138.24 138.24 (24.88) 113.36 31.36 27.66% 22.68% (24.88) 18.00 (6.88) SUBSTITUIÇÃO TRIBUTÁRIA 100.00 100.00 18% (18.00) 6.88 138.24 18% 24.88 106.88 B A C D 138.24 138.24 E 138.24 31.36 22.68% 22.68% (6.88) (6.88) (1)DRUGS 3 Categories for Drugs- Price Reference Basis (Mark-Up Basis) for VAT Calculation under "Substituição". 38,24% -Drug products that collect Pis/Pasep and Cofins taxes(also denominated positive list) . 33,00% -Drug products that does not collect Pis/Pasep and Cofins taxes( also denominated negative list). 41,38%- Drug Product is under no classification for Pis/Pasep and Cofins taxes( also denominated neutral list) (1)Cosmétics & Toiletries. IVA (Mark-Up Basis) for VAT Calculation under "Substituição". CAT 8 as of January 31, 2008. Parfums: 165,55% Deo Colonies, Skin Care, Permanents, products : 71,60%( any CFT product subsject to previous icms =vat @ 25%) Hair Care, Oral Care, bath& Shower, Men´s Toiletries, Baby Care:38.90%(any CFT product subject to previous icms=vat@ 12% or 18% no regime anterior de icms 7 6 L I f e E x p e c t VOLUME DE VENDAS NO COMÉRCIO VAREJISTA - ARTIGOS FARMACÊUTICOS, MÉDICOS, ORTOPÉDICOS, DE PERFURMARIA E COSMÉTICOS - CRESCIMENTO ACUMULADO EM 12 MESES Fonte: IBGE/PMC Elaboração: Bradesco I N c o m e 14,5% 12,18% 12,5% 10,83% 10,5% 9,87% 8,95% 8,5% 7,21% 6,31% 6,5% 6,83% 6,44% 5,68% 4,99% 4,39% jun/08 mar/08 dez/07 set/07 jun/07 set/06 jun/06 mar/06 dez/05 set/05 jun/05 mar/05 mar/07 3,50% 3,29% 2,5% 8 4,33% dez/06 4,5% dez/04 G r o w t h 7 Pharma Market - Brasil Brazilian Pharma & C.F.T Markets 30,000 Pharma Market Brasil - Units, Sales in R$ & USD(000) 25,000 CAGR11.8%aa 20,0000.35 30,000 32.48% 25,000 R$ 25,228 32.26% 15,0000.3 R$ 22,875 26.86% 20,190 14,985 16,934 13,428 11,84812,282 5,000 9,210 10,065 10,000 R$ 20,792 0.25 R$ 18,466 20,000 R$ 16,580 18.37% 15,000 12.60% 11.37% 00.2 $14,744 $11,147 $9,417 10,000 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 0.15 Source: Febrafarma (R$000) 0.1 C.F.T. - Brazilian Market 10.29% 10.02% $7,108 $5,603 5.16% 3.58% 5,000 6.67% 4.50% 0.05 251,585 1,486 1,422 1,352 1,305 0 2005 2006 2007 2008 15 Source: L 12 Months Base August- IMS Health Valor R$ Valor USD UNID Cresc R$ Cresc USD CAGR13.5%aa 0 20 2004 28,127 23,88325,908 10 Cresc UND 5.5 5.9 6.6 7.5 8.3 1997 1998 1999 2000 2001 9.7 11.5 17.5 13.5 19.6 15.4 5 0 2002 2003 2004 2005 2006 2007 Source: ABHIPEC R$ Billions( m.s.p. values) 9 8 Comparison Framework Highly Fragmented Market Number of Stores # of Drugstores Other Drugstore's chains 4% 58,745 55,591 12% ABRAFARMA Drugstore's chains1 3% Independent retailers 93% (51.213 stores) Total Revenues Brazil vs. US Other Drugstore's chains 15% + 60% # Drugstores per million habitants 40% 298 196 Independent retailers 60% Source: IMS Health as of 2006 Note: 1 Brazilian Drugstore Chains Association ABRAFARMA Drugstore's chains1 25% 23% US 1 Brazil Brazil 25% US Source: Census Bureau, IBGE NACDS and IMS as of 2006 Note: 1 Forecasted. Quotes any retail channel where pharmaceuticals are sold including traditional stand-alone drug stores, including supermarkets and department stores Scale is key for profitability Increase in regulatory framework and in competition should trigger the consolidation process in the pharmaceutical retail sector 10 9 Value Creation – Brand Loyalty- Consumer Respect – Intrinsic Values ...Shareholders … Clients ..Suppliers Chain of choice of our suppliers in new launchings. Drogasil increases its relevance as distribution channel for C&T + Pharma Industry. Strategic Points of Presence.. Geographic Predominance. Balance Sheet Structure.. TNS INTERSCIENCE AWARD •Affiliate Program Afinidade.(Drogasil convênios) •Affiliate Cards. • Delivery(Fone Farmácia). •Drogasil Credit Card … 11 10 DROGASIL- Services Call Center Drogasil CRM. Fone Farmácia Home Delivery. Dermocenter Skin Care Sales with Pharmacist Consultancy. Beauty Center Beauty and Make Up center with Sales Assitance from beauty specialists.. Programa Farmácia Popular do Brasil Developed by Brazilian Health Ministry offer discounts on selected drugs from therapeutic classes related to birh control, blood pressure, diabetes and obesity 12 Expansion - New Markets- Selective and Accretive Acquisitions. Store Locations: Drogalins: 10 Store locations in Goiania City ( August 21 , 2007). Company: Drogaria Vison- Drugstore chain acquisiton with 24 Stores in Brasilia D.F.(Feb 2008) Organic Growth: YTD OCT 2008- 15 Stores. Drogasil: Store Expansion with Consistent Financials 243 211 64 cities in Brasil 151 164 (October/08) 179 4,6% 3,3% 3,5% 2004 2005 2006 Store Number 13 6,1% 187 5,6% 6,0% 5,7% 2T07 2T08 5,1% 2007 EBITDA MARGIN-% Gross Revenue 12 Drogasil : Continuous Training Towards Service Excellence. .150,000 hours of employee training in 2007. YTD Sept 2008:151.144 Hours 782 pharmacists( as of Sept, 2008) for 249 stores. Pharmacists available during store working hours. Scholarship Program : Granted 53 scholarships for College Programs. Turn Over Drogasil: YTD Sept 2008: 25.23%. Number of Employees per area. 2006 Adm 2007 2008 2008 2008 1Q08 2Q08 3Q08 201 220 224 227 239 Distr.Center 271 314 366 380 418 Stores 2,989 3,714 3,803 4,395 4,501 Total 3,461 4,248 4,393 5,002 5,158 14 13 DROGASIL : Major Topics 2008 – Brief Update Buy Back Program : completed 3,7 MM shares as of October 2008. Total disbursement of R$46,952M. ABRASCA Value Creation Prize to Shareholders- First Edition –2008. July 29, 2008. Drogasil in Brasilia : Operation start up on July 21, 2008. Vison Merger into Drogasil: June 30, 2008. Electronic Invoice( NF-e) established to all Drogasil stores: March, 2008. Drugstore Chain Vison Acquisition: February 13, 2008. Guidance Revision Upwards- From 30 to 50 new store opennings in 2008. Feb 11,2008. Substituição Tributária(VAT Advance) starts in S.Paulo State: Feb 01, 2008. Buy Back Program introduction: Jan 17, 2008. 15 14 DROGASIL : Major Topics- Brief Update Dividends & I.O.C. 50% NET PROFIT 42.6% 35.2% 35.8% 33.8% 34.6% R$ 9,000 35% 28.5% 30% R$ 6,000 2007 1H 1H 22,312 10,837 Depreciation/Amortization 4,576 2,602 8,119 5,064 Interest Expenses (Income)net (5,955) 768 (11,160) 1,531 (230) 103 (135) 143 5,250 4,664 8,134 6,849 16,860 14,815 27,540 24,138 Income Tax EBITDA MARGIN (%GROSS REVENUE) 5.1% 6.0% 4.5% 5.1% R$ 3,000 R$ 5,931 10% 2008 6,884 EBITDA R$ 10,005R$ 9,522 15% 2Q07 12,759 Non Operating Result 25% 20% 2Q08 R$ 12,000 46.2% 45% 40% EBITDA RECONCILIATION R$ 4,500 R$ 3,366 5% R$ 2,824 R$ 2,354 R$ 2,848 R$ 4,500 R$ 3,075 0% R$ 0 2002 2003 2004 2005 2006 2007 2008 1H08 2Q07 2Q08 3Q07 3Q08 GROSS SALES EBITDA EBITDA MARGIN (% GROSS SALES) % NET PROFIT 608,541 469,181 16,860 14,815 27,540 24,138 5.1% 6.0% 4.5% 5.1% 1,300 Non Recurring Expenses: Vison Lay-Offs 480 480 Non Recurring Expenses: Vison Third Party Services 237 441 EBITDA Adjusted EBITDA Ajusted margin (% Gross Revenue Sales) 16 246,528 1,300 Discounts on Purchase - Interest Income IOC & Dividends 329,760 18,877 14,815 29,761 24,138 5.7% 6.0% 4.9% 5.1% 15 Growth with Efficiency 2Q07 2Q08 DRUGS Generic OTC DRUGS 73,6% Generic 14,8% OTC 19,6% Branded 75,3% 15,1% 21,3% Branded 65,6% 63,5% Non Drugs 0,0% 0,0% 24,7% 26,4% Non Drugs 20,0% 40,0% 60,0% 20,0% 40,0% 60,0% 80,0% 80,0% 5% 33% 36% Receivable Method – 2Q 2008 Caixa Cheques Cartão Débito Cheque Pré Cartão Crédito Convênios/Pbms 2% 3% 21% 17 16 DROGASIL: SAME STORE SALES 70% 58,8% 60% 55,9% 47,5% 50% 45,5% 44,4% 41,1% 40% 30% 22,7% 19,1% 20% 14,3% 10% 0% 11,6% 2004/03 15,6% 14,6% 17,3% 18,0% 16,5% 12,3% 11,3% 14,9% 2005/04 2006/05 2007 / 2006 1Q08 / 1Q07 2Q08 / 2Q07 Total + 3 Years - 3 Years DROGASIL 18 2Q 07 2Q08 Sales Area- Sq M2 total eop 25.588 32.331 Sales Area- Sq M2total- Avg in the period 25.301 32.074 Number of Stores- eop 187 243 Number of Stores- Avg in the period 185 241 Transactions 8.323 9.911 Number of Store Employees- eop 3.286 4.395 17 DROGASIL: Same Store Sales Index Analysis. Number of Stores at FY 2007 end:211 Stores Considered number of new stores opened until Sept 2008. STORES 4Q07 1Q08 2Q08 3Q08 4Q08 1Q09 2Q09 3Q09 4Q09 (+) 3 Years. 149 154 159 159 163 167 171 175 179 (-) 3 Years 30 29 27 35 47 47 72 73 69 Not Included in the Index 32 56 57 54 38 34 5 0 0 211 239 243 248 248 248 248 248 248 4 5 1 5 TOTAL Organic Growth Closed 19 18 Growth with Efficiency CAGR:24,4%% GROSS REVENUE R$Million 26,0% 1.000,0 23,1% GROSS MARGIN 24,1% 1.006,0 30% R$ 250 900,0 817,5 800,0 658,5 700,0 33,8% 600,0 522,8 R$ 200 23,0% 22,2% 23,1% 22,6% 22,5% 22,5% R$ 150 500,0 329,7 400,0 300,0 R$ 226,8 R$ 184,5 R$ 149,1 R$ 120,9 R$ 100 246,5 R$ 50 200,0 100,0 R$ 56,6R$ 73,2 10% R$ 0 - 2Q07 2Q08 2004 2005 2006 2007 2Q072Q08 Value R$millions 20 20% 2004 2005 2006 2007 Gross Margin-% on Gross Revenue 19 Growth with Efficiency- Performance BenchMark Drogasil X Abrafarma Monthly Sales/ Store 513 470.00 420 420.00 370.00 Drogasil X Abrafarma - Sales per Employee 320.00 25,000 270.00 23,500 22,372 22,000 220.00 Jul-07 Aug-07 Sep-07 Oct-07 Nov-07 Dec-07 Jan-08 Feb-08 Mar-08 Apr-08 May-08 Jun-08 Jul-08 BR Drogasil Drogasil XAbrafarma Abrafarma Transactions July 07=100Basis 20,500 23,207 21,275 20,816 21,710 22,589 22,789 21,577 20,999 16,000 140 17,042 17,762 16,925 19,150 18,787 18,128 17,621 23,414 22,972 20,187 19,000 17,500 23,661 16,631 17,692 17,871 17,144 18,195 15,626 14,500 13,000 130 115.18 110 105.37 104.92 100 100.00 102.89 100.21 97.49 108.27 102.96 99.83 96.01 114.19 Jul-07 Aug-07 Sep-07 Oct-07 Nov-07 Dec-07 Jan-08 Feb-08 Mar-08 Apr-08 May-08 Jun-08 110.28 108.10 105.60 10,000 116.51 114.07 104.05 102.65 100.70 101.86 11,500 123.27 122.07 120 Abrafarma BR Jul-08 Drogasil 103.70 94.45 90 80 Jul-07 Aug-07 Sep-07 Oct-07 Nov-07 Dec-07 Jan-08 Feb-08 Mar-08 Apr-08 May-08 Jun-08 Abrafarma BR Drogasil - Total Jul-08 21 20 Growth with Efficiency- Performance BenchMark ABRAFARMA BRAZIL 2006 GROSS SALES 6,804,195 7,892,692 2006 1,478,047 1,593,654 DROGASIL 2007 2006 5,986,682 6,886,601 16.0% SALES GROWTH GROSS PROFIT 2007 ABRAFARMA (-) Drogasil 2007 817,513 1,006,091 15.0% 23.1% 1,293,531 1,366,820 184,516 226,834 GROSS MARGIN 21.7% 20.2% 21.6% 19.8% 22.6% 22.5% NET PROFIT 80,087 62,731 59,292 29,975 20,795 32,756 ROS 1.18% 0.79% 0.99% 0.44% 2.54% 3.26% 168,167 141,770 129,916 90,505 38,251 51,265 2.47% 1.80% 2.17% 1.31% 4.68% 5.10% EBITDA EBITDA MARGIN Stores Dec-06 Dec-07 Aug-08 1842 2017 2190 ABRAFARMA -SP 630 684 748 DROGASIL 179 211 244 ABRAFARMA Brasil 22 21 Growth with Efficiency CAGR:42,5%% CAGR:60,7%% 57.5% NET PROFIT- Adjusted 32,8 35,0 25,0 85.0% 20,0 22.3% 20,8 3,2% 2,8% 10,0 7,91,5% 6,8 6,0% 40,0 3,0% 9,7 1,4% 20,0 5,0 1,0% 10,0 - 0,0% 2Q08 2004 R$ MM 2005 2006 5,7% 6,0% 38,3 5,1% 27.0% 30,0 2,0% 12,8 2Q07 51,3 32.2% 4,6% 2,5% 15,0 8,0% 63.4% 4,0% 50,0 3,9% 34.0% 5,0% 60,0 113.8% 30,0 EBITDA Adjusted R$ miillions 2007 18,8 3,3% 4,0% 3,5%23,4 17,7 14,8 2,0% 0,0% 2Q07 2Q08 2004 2005 2006 2007 % Rec. Bruta % Gross Revenue 23 22 24 30 29 28 27 23 25 25 23 25 24 26 28 33 35 33 38 42 46 50 52 55 57 58 55 57 59 57 62 61 62 68 68 67 66 65 64 62 61 61 59 58 56 56 55 54 56 54 52 52 54 54 52 53 55 52 56 58 58 60 59 58 58 58 57 54 55 56 53 52 50 49 48 53 52 54 52 55 55 54 61 59 60 61 62 58 59 69 70 72 Lojas jul-08 abr-08 abr-08 19 22 20 20 21 24 24 24 22 30 29 29 29 27 27 27 26 24 23 23 25 22 22 22 22 22 22 30 27 28 27 36 38 44 50 48 49 50 48 50 CD jan-08 out-07 18 18 17 23 22 22 21 23 24 24 24 23 33 29 28 30 29 30 32 29 41 44 DIAS EM ESTOQUE - TOTAL UNIDADES (MIL) jul-07 abr-07 jan-07 out-06 jul-06 abr-06 jan-06 out-05 jul-05 abr-05 23 22 26 25 25 26 Me jan-05 out-04 jul-04 abr-04 jan-04 out-03 jul-03 abr-03 jan-03 out-02 22 jul-02 22 34 32 32 32 33 32 32 30 35 34 30 35 33 31 31 31 28 28 32 28 32 31 28 31 30 30 29 29 29 27 29 29 32 32 27 31 29 32 30 31 32 30 31 31 33 33 31 33 31 33 31 32 32 31 34 30 32 31 29 32 32 33 30 31 30 30 30 29 31 29 26 28 27 25 24 24 24 24 abr-02 Working Capital Analysis: Days on Inventory Total 80 70 60 50 40 30 20 10 0 23 Gross Revenue Sales Net Sales 1H08 2Q 08 1H 07 2Q 07 608.541 570.375 329.757 316.630 469.181 388.630 246.528 204.293 Current Assets Checks Debit & Credit Cards Others (-) Provision for Bad Debt Taxes to recover Income Tax Inventories % Gross Sales % Gross Sales 0,7% 4.540 1,4% 8,9% 54.017 16,4% 1,3% 8.013 2,4% -0,1% (677) -0,2% 1,9% 11.800 3,6% 0,5% 3.045 0,9% 28,6% 174.286 52,9% 4.540 54.017 8.013 (677) 11.800 3.045 174.286 Current Liabilities Suppliers Taxes, Salaries 121.147 27.530 20.535 19,9% 4,5% 3,4% 121.147 27.530 20.535 36,7% 8,3% 6,2% 81.482 10.688 14.098 17,4% 2,3% 3,0% 81.482 10.688 14.098 33,1% 4,3% 5,7% Rentals Tenure Entitlement 2.351 105 0,4% 0,0% 2.351 105 0,7% 0,0% 1.721 252 0,4% 0,1% 1.721 252 0,7% 0,1% Current Assets Current Liabilities 255.024 171.669 255.024 171.669 W.I.> 83.355 13,7% Additional W.C> > 25.307 83.355 4,2% 17.168 % Gross Sales % Gross Sales 4.389 0,9% 4.389 1,8% 42.442 9,0% 42.442 17,2% 6.218 1,3% 6.218 2,5% (438) -0,1% (438) -0,2% 5.784 1,2% 5.784 2,3% 3.197 0,7% 3.197 1,3% 105.754 22,5% 105.754 42,9% 167.345 108.240 25,3% 5,2% 167.345 108.240 59.104 12,6% 59.104 24,0% 8.250 1,8% -71 0,0% Days on Receivables 19 18 20 19 Inventories 72 64 68 64 Suppliers 50 45 52 50 Cash Cycle 41 38 36 34 25 24 Growth with Efficiency EBITDA GROWTH.( L 12 M) X EV/EBITDA( L.12M) 25,0 40% 23,1 34% 35% 20,0 30% 27% 15,0 25% 15,0 13,4 17% 13,2 20% 11,7 15% 10,0 15% 10% 10% EBITDA X SALES GROWTH 5,0 5% 45,0% 20.000 R$ 18.877 0,0 18.000 0% 2Q07 3Q07 4Q07 EBITDA GROWTH. 1Q08 2Q08 16.000 34% R$ 14.353 R$ 14.815 EV/EBITDA 30,0% 33,8% R$ 12.814 21,9% 14.000 30,7% 27% 23,1% 12.000 R$ 10.720 10.000 20,8% 8.000 17% 15% 15,0% 6.000 10% 4.000 2.000 0,0% 0 2Q07 26 3Q07 EBITDA 4Q07 SALES GROWTH 1Q08 EBITDA GROWTH. 2Q08 25 Volume(R$000) and Share Price- DROG3 Evolution DROGASIL: DROG3 PERFORMANCE R$ 18,0 12.000 R$ 16,0 10.000 R$ 14,0 R$ 12,0 8.000 R$ 10,0 6.000 R$ 8,0 R$ 6,0 4.000 R$ 4,0 2.000 R$ 2,0 R$ 0,0 - fev/08 mar/08 abr/08 jun/08 DROG3 164 ranking in Bovespa Volume criteria YTD August 2008. DROG3 ADTV de R$1,600.0M (Jul 2008) DROG3 Performance : -37.32% compared to jul/08 ago/08 out/08 1.000 20 800 15 600 10 Ibovespa -42.648% YTD Oct 15, 2008.. 400 5 200 0 jan-05 fev-05 abr-05 mai-05 jun-05 ago-05 set-05 nov-05 dez-05 fev-06 mar-06 mai-06 jun-06 jul-06 set-06 out-06 dez-06 jan-07 mar-07 abr-07 jun-07 jul-07 ago-07 out-07 nov-07 jan-08 mar-08 abr-08 mai-08 jul-08 ago-08 out-08 0 27 Stock Price (R$) Rel. Brazil: Bovespa 26 DROG3: Research Coverage Investment Analyst Phone SAFRA Victor Martins (5511) 3175-7689 [email protected] Portuguese BRADESCO Fabio Monteiro/Ricardo Boiati (5511) 2178-5326 [email protected] English UBSPACTUAL Jander Medeiros (55 21)3262-9637 [email protected] English BULLTICK Diana Litewski (5511)3089 -8746 [email protected] English ITAU Luciano Campos/Marcio Osako (5511) 5029-4160 [email protected] English PROSPER Andre Segadilha (5521) 2138-8464 [email protected] (5511)3584-1675 [email protected] BANK/BROKER UNIBANCO Juliana Rozenbaum/Francine Martins E-Mail Reports IN 28 Portuguese English 27 SELL SIDE ESTIMATIVES Values ( R$000) Gross Sales 2008 2009 Net Profit 2008 2009 EBITDA 2008 TP 2009 Capital Stock 59,060,064 Shares Capital Stock R$ 285,400.0 Million 28,042,074 Shares Free Float UBS 1,319 1,575 49,000 55,000 63,900 78,700 R$ 11.3 % Free Float 41.36% ITAU 1,309 1,575 55,500 63,400 67,500 80,100 R$ 14.2 Share Price Oct 14, 2008 R$ 9.49 BULLTICK 1,293 1,635 49,000 71,000 65,000 101,000 R$13,7 IOC & DIVIDENDS FY 2007 R$ 10,004.80 Million UNIBANCO 1,317 1,711 55,000 65,000 68,000 87,000 R$ 17.6 IOC & Dividends YTD September 2008 R$ 14,021.60 Million Market Value R$ 560,480.0 Million (R$ 161,963.0) Million R$ 398,517.0 Million Net Debt( as of June 08) E.V EV/EBITDA(Ebitda e AVG.2008 ) 29 6.03 x 28 NGO Sponsorship- Social Commitment • Meu Primeiro Emprego, opportunity for youngs to have their First Job. • Projeto de Inclusão Social, Opportunity for Disability Persons to have a job. • AACD, Treatment and rehabilitation programs for children and adults with physical disabilities . • Instituto WCF Brasil, against child and adult abuse. • Ação Comunitária, Promotes social and education care for poor population in São Paulo city. • Doutores da Alegria, Bring Joy and Happiness to Children in hospitals. • Campanha do Agasalho, Forward sweaters and blankets collected in Drogasil stores to charity institutions. • Fundação Abrinq, Promotes citizenship of children and young adults. • Projeto “Obra do Berço”, Promotes education, health and social welfare to children and their families. 30 Q&A Drogasil S.A. Avenida Corifeu de Azevedo Marques, nº 3.097 Vila Butantã – São Paulo 0533905339-900 http://www.drogasil.com.br/ir Roberto Listik Investor RelationsRelations- Manager Tel.(5511) 37693769-5670 E-mail: mail: [email protected] Claúdio Roberto Ely CEO & Investor Relations Director E-mail: mail: [email protected] BRAZIL DAY 2008- DROG3 – October 28, 2008 31 30
Documentos relacionados
UNIBANCO ROADSHOW Rio de Janeiro- DROG3
jun-02 set-02 dez-02 mar-03 jun-03 set-03 dez-03 mar-04 jun-04 set-04 dez-04 mar-05 jun-05 set-05 dez-05 mar-06 jun-06 set-06 dez-06 mar-07 jun-07 set-07 dez-07 mar-08
Leia maishealthcare 1st trip
Deo Colonies, Skin Care, Permanents, products: 71,60%( any C& T product subject to previous icms-vat @ 25% ) Hair Care, Oral Care, Bath & Shower, Men´s Toiletries, Baby Care:38.90%( any C&T product...
Leia mais